-
The European Commission has tagged India-based pharma Alchem as being part of aglobal cartel that coordinates the pricing of a pharmaceutical ingredient in the antispasmodic drug Buscopan。
-
6/14/2024
Takeda（TSE:45002/NYSE:TAK）today announced the signing of anoption agreement with Ascentage Pharma to enter into an exclusive license agreement forolverembatinib，an oral，potentially best-in-class，third-generation BCR-ABL tyrosine kinase inhibitor（TKI），which is currently in development for chronic myeloid leukemia（CML）and other hematological cancers。
-
6/14/2024
Ascentage Pharma（6855 HK）announced today the signing of an option agreement with Takeda to enter into an exclusive license agreement for olverembatinib，an oral，potentially best-in-class third-generation BCR-ABL tyrosine kinase inhibitor（TKI），which is currently in development for chronimyed（CMumatleid）ological cancers。
-
6/14/2024
Novavax，Inc.（Nasdaq:NVAX），aglobal company advancing protein-based vaccines with its Matrix-M™adjuvant，today announced that it has submitted an amendment to its Emergency使用Authorization to the U.S.Food and Drug Administration（FDA）forits updated JN.1COVID-19vaccines aged12and older。
-
6/14/2024
Amgen（NASDAQ:AMGN）today announced the U.S.Food and Drug Administration（FDA）has approved BLINCYTO®（blinatumamab）for the treatment of adult and pediatric patients one month or older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia（B-ALL）in the consolidation phase，regardless of measurable residual disease（MRD）status。
-
6/14/2024
Cantargia Cantargia reported progress in the ongoing phase1clinical trial of the CAN10antibody.Seven dose groups have now been concluded without any safety concerns。
-
6/14/2024
Innovent Biologics，Inc.announced that clinical data of IBI363in advanced solid tumors are presented at the 2024ESMO Virtual Plenary。
-
6/14/2024
Editas Medicine，Inc.，aclinical-stage genome editing company，announced new safety and efficacy data in7 patients with transfusion-dependent beta thalassemia treated with renizgamglogene autogedtemcel in the Phase1/2Edithal clinical trial。
-
6/14/2024
Immune-Onc Therapeutics，Inc.announced the company will present additional positive interim Phase1b expansion cohort data for IO-202 in patients with chronic myelomyelomonocytic leukemia at the 2024 European Hematology Association Annual Meeting held virtually and in Madrid，Spain，June13–16。
-
6/14/2024
Venus Medtech，aleading provider of integrated solutions for transcatheter structural heart valvular therapies in China，announced that its in-house developed innovative transcatheter pulmonic valve replacement system，VenusP-Valve， has completed its first implantation in the PROTEUS IDE Pivotal Clinical Study at the University of Virginia School of Medicine。
-
6/14/2024
Protagonist Therapeutics，Inc.announced details from two abstracts at the European Hematology Association 2024 Congress，including an oral presentation with long-term follow-up data from the Phase2REVIVE study with rusfertide， a mimetic of the natural hormone hepcidin with potential therapeutic value in the treatment of polycythemia vera and other disease indications。
-
6/14/2024
Vertex Pharmaceuticals Incorporated announced longer-term data for CASGEVY™from global clinical trials in people with severe sickle cell disease or transfusion-dependent beta thalassemia。
-
6/14/2024
Kite，a Gilead Company，announced results from three new analyses for Yescarta®in relapsed/refractory large B-cell lymphoma，including both new clinical research and real-world evidence highlighting manufacturing and product characteristics of Yescarta，and outpatient administration of both Yescarta and Tecartus®at the 2024 European Hematology Association Annual Congress，June 13-16，Madrid。
-
6/14/2024
Pfizer Inc.announced detailed overall survival results from the Phase2 MagnetisMM-3study of ELREXFIO™in patients with heavily pretreated relapsed or refractory multiple myeloma。
-
6/14/2024
Rigel Pharmaceuticals，Inc.announced one oral and four poster presentations at the European Hematology Association 2024 Hybrid Congress in Madrid，Spain being held June 13-162024，and online。
-
6/14/2024
Editas Medicine，Inc.，aclinical-stage genome editing company，announced new safety and efficacy data in18 patients living with sickle cell disease treated with renizgamglogene autogedtemcel in the Phase1/2/3RUBY clinical trial。
-
6/14/2024
Sun Pharma and Israel-based Moebius Medical Limited presented data demonstrating the durability of pain relief achieved in symptomatic knee OA patients through26 weeks post injection of MM-II。
-
6/14/2024
Cabaletta Bio，Inc.reported positive initial clinical data from each of the first two patients dosed with CABA-201in the Phase1/2RESET-Myositis and RESET-SLE trials。
-
6/14/2024
Shattuck Labs，Inc.announced updated interim data from the Phase1Bdose expansion clinical trial of SL-172154in combination with AZA in frontline HR-MDS and TP53m AML patients。
-
6/14/2024
Zura Bio Limited，aclinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases，shared supportive data from a Phase1study evaluating its lead candiate，tibulizumab，for the treatment of Sjogren’s syndrome。
